Viva Biotech Overview

  • Status
  • Public

  • Employees
  • 2,213

Employees

  • Stock Symbol
  • 01873

Stock Symbol

  • Investments
  • 42

  • Share Price
  • $0.14
  • (As of Friday Closing)

Viva Biotech General Information

Description

Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Number 735 Ziping Road, Pudong New Area
  • Shanghai, 201318
  • China
+86 021
Primary Industry
Drug Discovery
Stock Exchange
HKG
Corporate Office
  • Number 735 Ziping Road, Pudong New Area
  • Shanghai, 201318
  • China
+86 021

Viva Biotech Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Viva Biotech Stock Performance

As of 20-Nov-2026, Viva Biotech’s stock price is $0.14. Its current market cap is $299M with 2.09B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.14 $0.15 $0.13 - $0.37 $299M 2.09B 4.64M $0.01

Viva Biotech Financials Summary

As of 30-Jun-2026, Viva Biotech has a trailing 12-month revenue of $272M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 334,695 525,475 308,518 541,177
Revenue 272,116 240,491 276,867 304,681
EBITDA 68,208 76,432 75,663 42,636
Net Income 25,443 30,559 23,315 (16,412)
Total Assets 1,014,445 1,028,945 965,822 1,050,971
Total Debt 132,187 190,173 175,895 268,490
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Viva Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Viva Biotech‘s full profile, request access.

Request a free trial

Viva Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceu
Drug Discovery
Shanghai, China
2,213 As of 2026

Shenyang, China
 

Tianjin, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Viva Biotech Competitors (2)

One of Viva Biotech’s 2 competitors is 3Sbio, a Formerly PE-Backed company based in Shenyang, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
3Sbio Formerly PE-Backed Shenyang, China
Asymchem Formerly VC-backed Tianjin, China
You’re viewing 2 of 2 competitors. Get the full list »

Viva Biotech Patents

Viva Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024031791-A1 Sample cryopreservation device for cryo-scanning electron microscope Inactive 10-Aug-2022
WO-2024021269-A1 Cryo-stage for cryo-electron microscope and control system therefor Inactive 28-Jul-2022
US-20240424113-A1 Conjugates comprising antifungals and heat shock protein 90 (hsp90) inhibitors and methods of use thereof Pending 19-Oct-2021
US-10329298-B2 Inhibitors of cellular metabolic processes Inactive 22-Aug-2017
US-20180079753-A1 Inhibitors of cellular metabolic processes Active 22-Aug-2017 C07D487/04
To view Viva Biotech’s complete patent history, request access »

Viva Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Viva Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Viva Biotech‘s full profile, request access.

Request a free trial

Viva Biotech Investments & Acquisitions (42)

Viva Biotech’s most recent deal was a Secondary Transaction - Private with Langhua Pharmaceutical for . The deal was made on 21-Sep-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Langhua Pharmaceutical 21-Sep-2023 Secondary Transaction - Private BPO/Outsource Services
Triumvira 21-Sep-2022 Later Stage VC Biotechnology
Apeiron (Drug Discovery) 29-Mar-2022 Early Stage VC Drug Discovery
BioCast Pharmaceutical 29-Nov-2021 Early Stage VC BPO/Outsource Services
Full Circles Therapeutics 01-Nov-2021 Early Stage VC Biotechnology
You’re viewing 5 of 42 investments and acquisitions. Get the full list »

Viva Biotech ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

32.69 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Viva Biotech’s complete esg history, request access »

Viva Biotech Exits (22)

Viva Biotech’s most recent exit was on 08-Jun-2021 from Gen House. The exit was categorized as with 7 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Gen House 08-Jun-2021 Completed
  • 7 buyers
Riparian Pharmaceuticals 01-Apr-2021 Completed
  • 2 buyers
DTx Pharma 21-Mar-2021 Completed
  • 18 buyers
Focus-X Therapeutics 10-Mar-2021 Completed
  • 3 buyers
Argonaut Genomics 01-Feb-2021 Accelerator/Incubator Completed
You’re viewing 5 of 22 exits. Get the full list »

Viva Biotech Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
SYNthesis ( Parkville, Australia 2007
Langhua Pharmaceutical Taizhou, China 2000

Viva Biotech FAQs

  • Where is Viva Biotech headquartered?

    Viva Biotech is headquartered in Shanghai, China.

  • What is the size of Viva Biotech?

    Viva Biotech has 2,213 total employees.

  • What industry is Viva Biotech in?

    Viva Biotech’s primary industry is Drug Discovery.

  • Is Viva Biotech a private or public company?

    Viva Biotech is a Public company.

  • What is Viva Biotech’s stock symbol?

    The ticker symbol for Viva Biotech is 01873.

  • What is the current stock price of Viva Biotech?

    As of 20-Nov-2026 the stock price of Viva Biotech is $0.14.

  • What is the current market cap of Viva Biotech?

    The current market capitalization of Viva Biotech is $299M.

  • What is Viva Biotech’s current revenue?

    The trailing twelve month revenue for Viva Biotech is $272M.

  • Who are Viva Biotech’s competitors?

    3Sbio and Asymchem are competitors of Viva Biotech.

  • What is Viva Biotech’s annual earnings per share (EPS)?

    Viva Biotech’s EPS for 12 months was $0.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process